First-in-class targeted treatment

TAVNEOS is the only targeted therapy for AAV (GPA/
MPA) to address a key driver of vascular
inflammation in the alternative complement pathway1,3

Efficacy

TAVNEOS reduces the pro-inflammatory effects of C5a, including:1

  • Neutrophil activation and migration
  • Adherence to sites of small blood vessel inflammation
  • Vascular endothelial cell retraction and permeability

TAVNEOS does not block the production of C5b, which is essential for the formation of the membrane attack complex (MAC)1

symptoms

Activation of the alternative complement pathway plays a key role in AAV, and no established therapies address this key driver of vascular inflammation1,3–9

Treatment recognised by EULAR 2022 and KDIGO 2024

The EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update recognised the ability of a TAVNEOS-based regimen to improve disease control, and the potential to lower GC toxicity and improve renal function10,11

symptoms

EULAR 2022 RECOMMENDATION LEVEL OF EVIDENCE 1b:

TAVNEOS (avacopan) in combination with RTX or CYC may be considered for induction of remission in GPA or MPA, as part of a strategy to substantially reduce exposure to GCs10

symptoms

Consider TAVNEOS in subgroups likely to have enhanced benefit vs GC therapy:10

  • patients at risk of development or worsening of GC-related adverse effects and complications
  • patients with active glomerulonephritis and rapidly deteriorating kidney function
symptoms

No data on the use of TAVNEOS beyond 1 year, so longer-term use cannot be recommended10

symptoms

In ADVOCATE, remission was sustained to Week 52 (primary endpoint) at a higher rate in the TAVNEOS-based regimen (65.7%) vs GC-based regimen (54.9%) so TAVNEOS appears to have efficacy for maintenance of remission 10

VIEW THE FULL EULAR RECOMMENDATIONS

The KDIGO 2024 clinical practice guideline for the management of ANCA-associated vasculitis recognises the ability of TAVNEOS in controlling disease, having the potential to improve renal function, reducing GC exposure and improving patient quality of life12

symptoms

KDIGO 2024 PRACTICE POINTS 9.3.1.1 AND 9.3.1.7:

TAVNEOS may be used as an alternative to GCs for induction of remission in combination with RTX or CYC12*

VIEW THE FULL KDIGO GUIDELINES
Reducing relapses

Please rotate your device

Understand more about the pathogenesis of AAV and how TAVNEOS works

*Recommendation 9.3.1.1: We recommend that GCs in combination with RTX or CYC be used as initial treatment of new-onset AAV (1B). Practice Point 9.3.1.7: Avacopan may be used as an alternative to GCs. Patients with an increased risk of GC toxicity are likely to receive the most benefit from avacopan. Patients with lower GFR may benefit from greater GFR recovery.12

 

AAV, ANCA-associated vasculitis; ANCA, anti-neutrophil cytoplasmic antibody; C5a, complement component 5a; C5b, complement component 5b; C5L2, C5a receptor-like 2; CYC, cyclophosphamide; EULAR, European Alliance of Associations for Rheumatology; GC, glucocorticoid; GFR, glomerular filtration rate; GPA, granulomatosis with polyangiitis; KDIGO, Kidney Disease: Improving Global Outcomes; MAC, membrane attack complex; MOA, mechanism of action; MPA, microscopic polyangiitis; RTX, rituximab.

1. Bekker P, et al. PLoS ONE 2016;11(10):e0164646. 2. Moiseev S, et al. Clin Exp Immunol 2020;202(3):394–402. 3. European Medicine Agency (2021). First-in-class medicine recommended for treatment of rare blood vessel inflammation. Available at: https://www.ema.europa.eu/en/news/first-class-medicine-recommended-treatment-rare-blood-vessel-inflammation. Date accessed: August 2024. 4. Hutton HL, et al. Semin Nephrol 2017;37(5):418–35. 5. Jennette JC, Nachman PH. Clin J Am Soc Nephrol 2017;12(10):1680–91. 6. Al-Hussain T, et al. Adv Anat Pathol 2017;24(4):226–34. 7. Lamprecht P, et al. EMJ Rheumatol 2021;8(1):36–42. 8. Liberman AC, et al. Front Endocrinol (Lausanne) 2018;9:235. 9. Nozaki Y. Front Immunol 2021;12:631055. 10. Hellmich B, et al. Ann Rheum Dis 2023;0:1–18. 11. Jayne D, et al. N Eng J Med 2021;384(7):599–609. 12. Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group. Kidney Int 2024;105(3S):S71–116.